A multi-center phase Ib trial evaluating the safety and efficacy of lacutamab in patients with relapsed/refractory peripheral T-cell lymphoma that express KIR3DL2
MD Anderson Study Status
This is a multi-center phase Ib sutdy, which evaluates the safety and efficacy of lacutamab monotherpy in patients with relapse peripheral T-cell lymphoma that express KIR3DL2.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Peripheral T Cell Lymphoma
For general questions about clinical trials: